Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 240 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR An Alternative Model for Genetic Testing Delivery Proposed with Posttest Counselling... October 4, 2023 Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... November 14, 2019 EMA Recommends Extension of Indications for Durvalumab in the Management of... October 25, 2023 N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by... January 23, 2026 Load more HOT NEWS Getting through the Holidays-With a Little Help From Oncolink Cancer in My Community: Working Toward Early Diagnosis for Children With... EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says
